Long‐Term Outcomes and Quality of Life of Children With Intracranial Ependymoma Treated With Pencil Beam Scanning Proton Therapy
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Eymeric Le Reun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland. Hauptthemen laut MEDLINE: Ependymoma, Proton Therapy, Quality of Life, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Ependymoma is a common brain tumor in children and adolescents. Adjuvant radiation therapy improves prognosis but carries potential toxicity risks, particularly for young patients. Proton therapy (PT) offers better conformal treatments and reduces dose exposure compared to traditional photon radiotherapy. Procedure This study retrospectively analyzed long‐term outcomes of children treated with pencil beam scanning (PBS) PT for intracranial ependymomas (EPs) at the Paul Scherrer Institute (PSI) between 2004 and 2022.
Results
We identified 119 children, with most having infra‐tentorial tumors (70.6%) and anaplastic ependymomas (82.4%). The median PT dose was 59.4 Gy RBE delivered in 1.8 Gy RBE /fraction. Follow‐up at 5 years showed 70.4% local control, 63.5% progression‐free survival (PFS), and 82.2% overall survival (OS). OS was better with upfront than relapse treatment (83% vs. 69.8%; p = 0.024), and complete resection improved both LC (74% vs. 65.1%; p = 0.033) and PFS (67.5% vs. 57.1%; p = 0.049) compared to subtotal resection. No hearing loss was observed with cochlea D max not exceeding 48 Gy RBE (10.5% vs. 0%; p = 0.0097), whereas the risk of hormone deficiency was significantly increased with pituitary D mean above 38 Gy RBE (33.3% vs. 6.0%; p = 0.00007). Most patients (72.3%) had no late toxicity. Four secondary brain malignancies (3.4%) occurred within a median of 9.3 years after PT (range: 3.7–15). Quality of life 5 years after PT was good in older (>4 years) patients, though proxy‐rated social functioning was poorer than the norm group.
Conclusion
Intracranial PBS‐PT offers excellent tumor control and low late toxicity, and revealed good overall quality of life in children with ependymoma, both by proxy‐ and self‐assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
- Inserm, U1296 Unit, "Radiation: Defense, Health and Environment", Centre Léon-Bérard, Lyon, France.
- Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
ORCID-Profile: Eymeric Le Reun, Ilya Kotov, Dominic Leiser
Zitieren
APA
Le Reun, E., Kotov, I., Leiser, D., Pica, A., Vazquez, M., Calaminus, G., & Weber, D. C. (2025). Long‐Term Outcomes and Quality of Life of Children With Intracranial Ependymoma Treated With Pencil Beam Scanning Proton Therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31728
Vancouver
Le Reun E, Kotov I, Leiser D, Pica A, Vazquez M, Calaminus G, et al. Long‐Term Outcomes and Quality of Life of Children With Intracranial Ependymoma Treated With Pencil Beam Scanning Proton Therapy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31728
BibTeX
@article{LeReun2025,
author = {Le Reun, Eymeric and Kotov, Ilya and Leiser, Dominic and Pica, Alessia and Vazquez, Miriam and Calaminus, Gabriele and Weber, Damien Charles},
title = {Long‐Term Outcomes and Quality of Life of Children With Intracranial Ependymoma Treated With Pencil Beam Scanning Proton Therapy},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31728}
}
EUVIMED